• Record revenue of $111.5 million, up 21.6% on FY24
• Returned to positive EBITDA of $9.2 million
• Achieved milestone of treating over 1 million patients globally

SomnoMed Ltd has reported an exceptional FY25, achieving record financial performance and reaching a significant industry milestone. The company generated revenue of $111.5 million, a 21.6% increase on the prior year, marking the first time it has surpassed $100 million in annual revenue. The operational improvement program launched in FY24 continued to deliver strong results, with increased production capacity enabling the company to better meet growing global demand and reduce order backlogs. This, combined with effective cost management, allowed SomnoMed to return to positive EBITDA of $9.2 million. The company also reached the milestone of becoming the first oral appliance company in the world to have treated more than one million patients to date, a testament to the trust placed in SomnoMed by clinicians and patients worldwide. Innovation remains central to the company's growth strategy, with the FDA clearance for compliance tracking and supporting systems for the Rest Assure product, the first oral appliance with inbuilt compliance monitoring, a key achievement. Looking ahead, SomnoMed will focus on sustainable revenue and margin growth, expanding manufacturing capacity, and continuing the development of Rest Assure, which it believes will further strengthen its leadership position and open new opportunities.

For FY26, SomnoMed provides the following guidance: - Revenue: between $119 million and $126 million - EBITDA: between $10 million and $12 million - Capex: between $6 million and $8 million